7XRZ
 
 | | Crystal structure of BRIL and SRP2070_Fab complex | | 分子名称: | IGG HEAVY CHAIN, IGG LIGHT CHAIN, Soluble cytochrome b562 | | 著者 | Suzuki, M, Miyagi, H, Yasunaga, M, Asada, H, Iwata, S, Saito, J. | | 登録日 | 2022-05-12 | | 公開日 | 2023-05-10 | | 最終更新日 | 2023-11-29 | | 実験手法 | X-RAY DIFFRACTION (2.1 Å) | | 主引用文献 | Structural insight into an anti-BRIL Fab as a G-protein-coupled receptor crystallization chaperone.
Acta Crystallogr D Struct Biol, 79, 2023
|
|
7C6A
 | | Crystal structure of AT2R-BRIL and SRP2070_Fab complex | | 分子名称: | IgG Light Chain, IgG heavy chain, SAR1, ... | | 著者 | Suzuki, M, Miyagi, H, Asada, H, Yasunaga, M, Suno, C, Takahashi, Y, Saito, J, Iwata, S. | | 登録日 | 2020-05-21 | | 公開日 | 2020-07-29 | | 最終更新日 | 2023-11-29 | | 実験手法 | X-RAY DIFFRACTION (3.4 Å) | | 主引用文献 | The discovery of a new antibody for BRIL-fused GPCR structure determination.
Sci Rep, 10, 2020
|
|
7C61
 | | Crystal structure of 5-HT1B-BRIL and SRP2070_Fab complex | | 分子名称: | 5-hydroxytryptamine receptor 1B,Soluble cytochrome b562,5-hydroxytryptamine receptor 1B, Ergotamine, IGG HEAVY CHAIN, ... | | 著者 | Suzuki, M, Miyagi, H, Asada, H, Yasunaga, M, Suno, C, Takahashi, Y, Saito, J, Iwata, S. | | 登録日 | 2020-05-21 | | 公開日 | 2020-07-29 | | 最終更新日 | 2023-11-29 | | 実験手法 | X-RAY DIFFRACTION (3 Å) | | 主引用文献 | The discovery of a new antibody for BRIL-fused GPCR structure determination.
Sci Rep, 10, 2020
|
|
3AFO
 | | Crystal Structure of Yeast NADH Kinase complexed with NADH | | 分子名称: | (4S)-2-METHYL-2,4-PENTANEDIOL, 1,4-DIHYDRONICOTINAMIDE ADENINE DINUCLEOTIDE, NADH kinase POS5 | | 著者 | Ando, T, Ohashi, K, Ochiai, A, Miyagi, H, Kawai, S, Mikami, B, Murata, K. | | 登録日 | 2010-03-10 | | 公開日 | 2011-03-16 | | 最終更新日 | 2023-11-01 | | 実験手法 | X-RAY DIFFRACTION (2 Å) | | 主引用文献 | The structural factor conferring NADH kinase activity on yeast mitochondrial Pos5
To be Published
|
|
8GNG
 | | Crystal structure of human adenosine A2A receptor in complex with istradefylline. | | 分子名称: | (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate, 8-[(~{E})-2-(3,4-dimethoxyphenyl)ethenyl]-1,3-diethyl-7-methyl-purine-2,6-dione, Adenosine receptor A2a, ... | | 著者 | Suzuki, M, Saito, J, Miyagi, H, Yasunaga, M. | | 登録日 | 2022-08-23 | | 公開日 | 2023-03-22 | | 最終更新日 | 2023-11-29 | | 実験手法 | X-RAY DIFFRACTION (3.2 Å) | | 主引用文献 | In Vitro Pharmacological Profile of KW-6356, a Novel Adenosine A 2A Receptor Antagonist/Inverse Agonist.
Mol.Pharmacol., 103, 2023
|
|
8GNE
 | | Crystal structure of human adenosine A2A receptor in complex with an insurmountable inverse agonist, KW-6356. | | 分子名称: | (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate, 2-{2-[2-(2-{2-[2-(2-ETHOXY-ETHOXY)-ETHOXY]-ETHOXY}-ETHOXY)-ETHOXY]-ETHOXY}-ETHANOL, Adenosine receptor A2a,Soluble cytochrome b562, ... | | 著者 | Suzuki, M, Saito, J, Miyagi, H, Yasunaga, M. | | 登録日 | 2022-08-23 | | 公開日 | 2023-03-22 | | 最終更新日 | 2023-11-29 | | 実験手法 | X-RAY DIFFRACTION (2.3 Å) | | 主引用文献 | In Vitro Pharmacological Profile of KW-6356, a Novel Adenosine A 2A Receptor Antagonist/Inverse Agonist.
Mol.Pharmacol., 103, 2023
|
|
7C6B
 | | Crystal structure of Ago2 MID domain in complex with 6-(3-(2-carboxyethyl)phenyl)purine riboside monophosphate | | 分子名称: | 3-[3-[9-[(2R,3R,4S,5R)-3,4-bis(oxidanyl)-5-(phosphonooxymethyl)oxolan-2-yl]purin-6-yl]phenyl]propanoic acid, PHOSPHATE ION, Protein argonaute-2 | | 著者 | Suzuki, M, Takahashi, Y, Saito, J, Miyagi, H, Shinohara, F. | | 登録日 | 2020-05-21 | | 公開日 | 2020-11-25 | | 最終更新日 | 2023-11-29 | | 実験手法 | X-RAY DIFFRACTION (1.7 Å) | | 主引用文献 | siRNA potency enhancement via chemical modifications of nucleotide bases at the 5'-end of the siRNA guide strand.
Rna, 27, 2021
|
|
7D7U
 | | Crystal structure of Ago2 MID domain in complex with 8-Br-adenosin-5'-monophosphate | | 分子名称: | 8-BROMO-ADENOSINE-5'-MONOPHOSPHATE, Protein argonaute-2 | | 著者 | Suzuki, M, Takahashi, Y, Saito, J, Miyagi, H, Shinohara, F. | | 登録日 | 2020-10-06 | | 公開日 | 2020-11-25 | | 最終更新日 | 2023-11-29 | | 実験手法 | X-RAY DIFFRACTION (2 Å) | | 主引用文献 | siRNA potency enhancement via chemical modifications of nucleotide bases at the 5'-end of the siRNA guide strand.
Rna, 27, 2021
|
|
5ETY
 | | Crystal Structure of human Tankyrase-1 bound to K-756 | | 分子名称: | 3-[[1-(6,7-dimethoxyquinazolin-4-yl)piperidin-4-yl]methyl]-1,4-dihydroquinazolin-2-one, Tankyrase-1, ZINC ION | | 著者 | Takahashi, Y, Miyagi, H, Suzuki, M, Saito, J. | | 登録日 | 2015-11-18 | | 公開日 | 2016-06-22 | | 最終更新日 | 2024-03-20 | | 実験手法 | X-RAY DIFFRACTION (2.9 Å) | | 主引用文献 | The Discovery and Characterization of K-756, a Novel Wnt/ beta-Catenin Pathway Inhibitor Targeting Tankyrase
Mol.Cancer Ther., 15, 2016
|
|
7CE4
 | | Tankyrase2 catalytic domain in complex with K-476 | | 分子名称: | 5-[3-[[1-(6,7-dimethoxyquinazolin-4-yl)piperidin-4-yl]methyl]-2-oxidanylidene-4H-quinazolin-1-yl]-2-fluoranyl-benzenecarbonitrile, Poly [ADP-ribose] polymerase tankyrase-2, SULFATE ION, ... | | 著者 | Takahashi, Y, Suzuki, M, Saito, J. | | 登録日 | 2020-06-22 | | 公開日 | 2021-05-12 | | 最終更新日 | 2023-11-29 | | 実験手法 | X-RAY DIFFRACTION (1.5 Å) | | 主引用文献 | The dual pocket binding novel tankyrase inhibitor K-476 enhances the efficacy of immune checkpoint inhibitor by attracting CD8 + T cells to tumors.
Am J Cancer Res, 11, 2021
|
|
